Celldex Reports Promising Phase 2 Results for Barzolvolimab in Chronic Spontaneous Urticaria, Showing Sustained Clinical Benefits Seven Months Post-Treatment

Celldex (CLDX) announced positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU), revealing that 41% of patients experienced complete response seven months post-treatment, and 48% reported CSU no longer impacting their quality of life. The drug, which targets mast cells, demonstrated a favorable safety profile and sustained improvements in urticaria activity scores. Enrollment in Phase 3 trials is ongoing, with analysts issuing buy ratings on the stock, though some institutional investors decreased their positions.

Analysis

Celldex (CLDX) has presented compelling new long-term efficacy and quality of life data from its Phase 2 study of barzolvolimab in chronic spontaneous urticaria (CSU), with 41% of patients on the 150mg Q4W dose maintaining a complete response (UAS7=0) and 48% reporting no impact on quality of life (DLQI=0/1) at 76 weeks, seven months post-treatment. The drug, which targets mast cells by inhibiting the receptor tyrosine kinase KIT, demonstrated a favorable safety profile with predominantly Grade 1, reversible mechanism-related adverse events, such as resolved neutropenia and reversible hair/skin pigmentation changes, and no new safety signals identified through 76 weeks. These results, showing sustained UAS7 improvements and clinical benefit in over 90% of patients, including those refractory to prior biologic treatment omalizumab, position barzolvolimab as a potentially transformative treatment. Celldex is actively enrolling patients in two global Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2), a critical step towards potential commercialization. Wall Street sentiment appears positive, with Morgan Stanley issuing an "Overweight" rating and Citigroup a "Buy" rating in early 2025. However, institutional ownership changes in Q1 2025 were mixed: notable new investments by Commodore Capital LP (3.2M shares, an estimated $58M) and increased stakes by Kynam Capital Management and UBS Group AG contrast with significant reductions or complete exits by Jefferies Financial Group (removed 97.7%) and T. Rowe Price Investment Management (removed 100%), following complete divestitures by Jennison Associates LLC and Logos Global Management LP in Q4 2024. This divergence highlights varying institutional perspectives despite the positive clinical trajectory and the inherent development risks associated with Phase 3 execution and reliance on forward-looking statements.

Key Decisions for Investors

• Investors should view the robust Phase 2 data and sustained efficacy of barzolvolimab, particularly the 41% complete response rate at 76 weeks, as a significant positive, warranting close attention to the progress of ongoing Phase 3 trials which are critical for de-risking the asset.
• Upcoming catalysts, including Phase 3 enrollment updates and subsequent interim and final data readouts from the EMBARQ trials, should be closely monitored as they could substantially impact Celldex's valuation and market perception.
• The divergent institutional investor activity in CLDX, featuring both new large investments by funds like Commodore Capital and substantial or complete exits by others such as Jefferies and T. Rowe Price, merits careful assessment as a potential indicator of differing risk appetites or convictions regarding the company's long-term prospects versus the near-term clinical and financial risks.
• It is prudent to acknowledge the inherent risks in late-stage clinical development, the timeline to potential regulatory approval and commercialization, and the potential for adverse events despite a currently favorable safety profile when evaluating an investment in CLDX.